1. Background
2. Objectives
3. Methods
3.1. Specimens
3.2. Sample Processing and RNA Extraction
3.3. One Step Real-Time PCR Testing
| Name | Sequence (5’ > 3’) | Working Concentration, µM | |
|---|---|---|---|
| Influenza A | Primer F | GACCRATCCTGTCACCTCTGAC | 40 |
| Primer R | AGGGCATTYTGGACAAAKCGTCTA | 40 | |
| Probea | TGCAGTCCTCGCTCACTGGGCACG | 10 | |
| SW Inf A | Primer F | GCACGGTCAGCACTTATYCTRAG | 10 |
| Primer R | GTGRGCTGGGTTTTCATTTGGTC | 10 | |
| Probeb | CYACTGCAAGCCCA”T” ACACACAAGCAGGCA | 10 | |
| H3N2 | Primer F | AAGCATTCCYAATGACAAACC | 10 |
| Primer R | ATTGCRCCRAATATGCCTCTAGT | 10 | |
| Probe | CAGGATCACATATGGGSCCTGTCCCAG | 10 | |
| Influenza B | Primer F | GAGACACAATTGCCTACCTGCTT | 10 |
| Primer R | TTCTTTCCCACCGAACCAAC | 10 | |
| Probe | AGAAGATGGAGAAGGCAAAGCAGAACTAGC | 10 | |
| RNAase P | Primer F | AGATTTGGACCTGCGAGCG | 10 |
| Primer R | GAGCGGCTGTCTCCACAAGT | 10 | |
| Probe | TTCTGACCTGAAGGCTCTGCGCG | 10 |
aTaqMan probes consist of FAM reporter (5’-end with the reporter molecule 6-carboxyfluorescein) and BHQ1quencher (Blackhole Quencher 1) at the 3’-end.
bQuenched internally at a modified”T” residue with BHQ1, to prevent probe extension by Taq polymerase (11).
4. Results
| Characteristics | No. Samples Tested | No. of Influenza Cases | No. of Influenza Cases | |||
|---|---|---|---|---|---|---|
| A (H3N2) | A (H1N1) pdm09 | Type B | Type A and B | |||
| Year | ||||||
| 2010 - 2014 | 790 | 68 (8.6) | 21 (30.8) | 25 (36.7) | 22 (32.3) | 0 |
| Gender | ||||||
| Male | 72 | 7 (10.3) | 4 (57.1) | 1 (14.3) | 2 (28.6) | 0 |
| Female | 718 | 61 (89.7) | 17 (27.9) | 24 (39.3) | 20 (32.8) | 0 |
| Age group, y | ||||||
| 1 to 14 | 32 | 2 (2.9) | 1 (50) | 1 (50) | 0 | 0 |
| 15 to 24 | 227 | 20 (29.4) | 5 (25) | 8 (40) | 7 (35) | 0 |
| 25 - 34 | 354 | 28 (41.2) | 8 (28.6) | 12 (42.8) | 8 (28.6) | 0 |
| 35 to 44 | 83 | 9 (13.2) | 5 (55.6) | 3 (33.3) | 1 (11.1) | 0 |
| 45 to 54 | 42 | 4 (5.9) | 0 | 0 | 4 (100) | 0 |
| 55 to 64 | 30 | 3 (4.4) | 2 (66.7) | 1 (33.3) | 0 | 0 |
| Over 65 | 22 | 2 (2.9) | 0 | 0 | 2 (100) | 0 |
| Total | 790 | 68 (8.6) | 21 (30.8) | 25 (36.7) | 22 (32.3) | 0 |
aValues are expressed as No. (%).
| Variable | Confirmed Cases (68 Cases) | Unconfirmed Cases (722 Cases) | P Value | |
|---|---|---|---|---|
| Sex | Male | 7 (10.3) | 65 (9) | 0.07 |
| Female | 61 (89.7) | 657 (91) | ||
| Residency | Urban | 21 (30.9) | 216 (29.9) | 0.5 |
| Rural | 47 (69.1) | 506 (70.1) | ||
| Hospitalization | Yes | 16 (23.5) | 228 (31.6) | 0.2 |
| No | 52 (76.5) | 494 (48.4) | ||
| Pregnancy | Yes | 28 (41.2) | 255 (35.3) | 0.01 |
| No | 40 (58.8) | 467 (64.7) |
aValues are expressed as No. (%).
| Positive Sample | Clinical Symptoms and Tests | ||||
|---|---|---|---|---|---|
| Fever | Cough | Myalgia | Sore throat | Rhinorrhea | |
| pH1N1 | 24 (96) | 24 (96) | 22 (88) | 10 (40) | 15 (60) |
| H3N2 | 20 (95.2) | 19 (90.4) | 16 (76.1) | 11 (52.3) | 12 (57.1) |
| B | 20 (90.9) | 21 (95.4) | 16 (72.7) | 16 (72.7) | 11 (50) |
aValues are expressed as No. (%).
5. Discussion
| Study | Year | Influenza Cases, % | |||
|---|---|---|---|---|---|
| A (H3N2) | A (H1N1) pdm09 | Type B | |||
| Dashti-Khavidaki et al. | 2009 | Iran-Tehran | - | 34.5 | - |
| Afrasiabian et al. | 2009 | Iran-Kurdestan | - | 14.8 | - |
| Gao et al. | 2009 | USA | - | 19.5 | - |
| Monsef et al. | 2013 | Iran-Hamedan | - | 63.8 | - |
| Jedary Seifi et al. | 2014 | Iran-Tabriz | - | 20.3 | - |
| Haghshenas et al. | 2011 - 2013 | Iran-Mazandaran | 35.2 | - | - |
| Hajikhezri et al. | 2009 - 2010 | Iran-Ahvaz | 6.8 | - | 0.7 |
| Gaini et al. | 200 - 2013 | Global study | - | - | 22.6 |
| Qi et al. | 2011 - 2015 | china | 44.7 | 21 | 34.1 |

